Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes

Xu, Siyuan; Huang, Hui; Qian, Ji; Liu, Yang; Huang, Ying; Wang, Xiaolei; Liu, Shaoyan; Xu, Zhengang; Liu, Jie

doi:10.1001/jamanetworkopen.2021.18526

Cited by 74 publications

(47 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, our findings showed that PTC patients with HT were also less likely to develop recurrence and have a higher 20-year survival rate, which were in agreement with prior studies [ 41 , 66 ]. Although we did not find the presence of HT indicates lower disease-specific deaths, a recent study by Hu et al reported that patients with HT had lower rates of tumor recurrence, and lower disease-related mortality compared with patients without HT [ 79 ]. Kashima et al [ 13 ] reported a 0.7% cancer specific mortality and a 95% relapse-free 10-year survival rate in patients with HT compared to a 5% mortality and 85% relapse-free 10-year survival rate without chronic thyroiditis.…”

Section: Discussioncontrasting

confidence: 89%

Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis

Tang¹,

Pan²,

Peng³

2022

PLoS ONE

View full text Add to dashboard Cite

Objective To assess association between Hashimoto thyroiditis (HT) and clinical outcomes of papillary thyroid carcinoma (PTC). Methods Databases including Pubmed, Embase, Cochrane Library, and Web of Science were searched. Weighed mean differences (WMDs) and odds ratios (ORs) were used to evaluate association between HT and clinical outcomes of PTC, and the effect size was represented by 95% confidence intervals (CIs). Heterogeneity test was performed for each indicator. If the heterogeneity statistic I2≥50%, random-effects model analysis was carried out, otherwise, fixed-effect model analysis was performed. Sensitivity analysis was performed for all outcomes, and publication bias was tested by Begg’s test. Results Totally 47,237 patients in 65 articles were enrolled in this study, of which 12909 patients with HT and 34328 patients without HT. Our result indicated that PTC patients with HT tended to have lower risks of lymph node metastasis (OR: 0.787, 95%CI: 0.686–0.903, P = 0.001), distant metastasis (OR: 0.435, 95%CI: 0.279–0.676, P<0.001), extrathyroidal extension (OR: 0.745, 95%CI: 0.657–0.845, P<0.001), recurrence (OR: 0.627, 95%CI: 0.483–0.813, P<0.001), vascular invasion (OR: 0.718, 95%CI: 0.572–0.901, P = 0.004), and a better 20-year survival rate (OR: 1.396, 95%CI: 1.109–1.758, P = 0.005) while had higher risks of multifocality (OR: 1.245, 95%CI: 1.132–1.368, P<0.001), perineural infiltration (OR: 1.922, 95%CI: 1.195–3.093, P = 0.007), and bilaterality (OR: 1.394, 95%CI: 1.118–1.739, P = 0.003). Conclusions PTC patients with HT may have favorable clinicopathologic characteristics, compared to PTCs without HT. More prospective studies are needed to further elucidate this relationship.

show abstract

Section: Discussioncontrasting

confidence: 89%

Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis

Tang¹,

Pan²,

Peng³

2022

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Our study implies that the clinicopathological features of PTC/HT(+) are different from those of PTC/HT(-), which is similar to other results ( 7 – 9 , 19 , 20 ) In addition, our result indicates that lncRNAs and mRNAs may play an important role in establishing the different clinical characteristics between patients with PTC/HT(+) and PTC/HT(-). If we can find out the specific mechanism, it may bring new clinical methods to the diagnosis and treatment of PTC combined HT.…”

Section: Discussionsupporting

confidence: 85%

“…The association between HT and PTC was first described in 1955. Since then, an increasing number of studies have investigated the association between HT and PTC, and many studies showing that the clinicopathological features of PTC complicated with HT [PTC/HT (+)] are different from those of PTC without HT [PTC/HT (-)] ( 7 – 9 ). Compared with PTC/HT (-), PTC/HT (+) is associated with a lower VI lymph node metastasis rate, lower-stage disease, and less disease persistence, but the molecular mechanisms underlying these differences remain unelucidated.…”

Section: Introductionmentioning

confidence: 99%

Identification of Long Noncoding RNAs Associated With the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated With Hashimoto’s Thyroiditis

Ding

Peng

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) play a significant role in cancer biology. This study aimed to determine the roles of lncRNAs in establishing the differences in clinical features between patients with papillary thyroid carcinoma (PTC) without Hashimoto’s thyroiditis (HT) and patients with PTC and HT. In the present study, we detected the differentially expressed lncRNAs between tumor tissues of patients with PTC with or without HT through lncRNA microarrays. The data were verified and analyzed through qRT-PCR, cell viability, cell cycle and bioinformatics analyses. We found that 1031 lncRNAs and 1338 mRNAs were abnormally expressed in 5 tissue samples of PTC complicated with HT [PTC/HT (+)] compared with 5 samples of PTC without HT [PTC/HT (-)]. Gene Ontology and pathway analyses of the mRNAs suggested that several biological processes and pathways, particularly immune system processes, were induced in the PTC/HT (+) tissues. Twenty lncRNAs were verified in 31 PTC/HT (+) and 64 PTC/HT (-) specimens by qRT-PCR, and the results were consistent with the microarray data. Specifically, ENST00000452578, a downregulated lncRNA in PTC/HT(+), was negatively correlated with the tumor size. Cell viability assays revealed that ENST00000452578 could inhibit cell proliferation. Our results indicate that lncRNAs and mRNAs play an important role in establishing the different clinical characteristics between patients with PTC/HT(+) and patients with PTC/HT(-), and might provide new insights from the perspective of RNA for obtaining a further understanding of the clinical features related to PTC with HT.

show abstract

“…Many authors have reported a considerably better prognosis of DTC when HT is also present; however, these data are not uniform in the various studies, as some report a greater presence of multifocal carcinomas and a similar recurrence rate to non-HT tumors ( 20 , 21 ), while others show a greater presence of microcarcinomas, with a smaller average tumor size and a lower incidence of lymph node metastases and extrathyroidal extension, leading to significantly better disease-free survival for DTCs with concomitant HT than for those without HT ( 16 , 22 , 23 , 38 ).…”

Section: Discussionmentioning

confidence: 99%

Association between hashimoto thyroiditis and differentiated thyroid cancer: A single-center experience

et al. 2022

View full text Add to dashboard Cite

Hashimoto’s thyroiditis is the most common cause of hypothyroidism in the iodine-sufficient areas of the world. Differentiated thyroid cancer is the most common thyroid cancer subtype, accounting for more than 95% of cases, and it is considered a tumor with a good prognosis, although a certain number of patients experience a poor clinical outcome. Hashimoto’s thyroiditis has been found to coexist with differentiated thyroid cancer in surgical specimens, but the relationship between these two entities has not yet been clarified. Our study aims to analyze the relationship between these two diseases, highlighting the incidence of histological diagnosis of Hashimoto thyroiditis in differentiated thyroid cancer patients, and assess how this autoimmune disorder influences the risk of structural disease recurrence and recurrence rate.

show abstract

Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes

Cited by 74 publications

References 27 publications

Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis

Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis

Identification of Long Noncoding RNAs Associated With the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated With Hashimoto’s Thyroiditis

Association between hashimoto thyroiditis and differentiated thyroid cancer: A single-center experience

Contact Info

Product

Resources

About